Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.40 |
| ▸ | WNT3A | P56704 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 15/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | KDM1B | Q8NB78 | 3/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20656971 | 1.00 | PRKCI (0.41) | PRKCICLK1DYRK1ADYRK1BCTNNB1 | |
| SCHEMBL12971946 | 0.90 | PRKCI (0.47) | PRKCIDYRK1ADYRK1BKDM1AKCNH2 | |
| SCHEMBL20656890 | 0.90 | PRKCI (0.47) | PRKCIDYRK1ADYRK1BKDM1AKCNH2 | |
| SCHEMBL23653045 | 0.78 | DYRK1A (0.43) | PRKCICLK1DYRK1ADYRK1BCTNNB1 | |
| SCHEMBL12971972 | 0.75 | KDM1A (0.46) | KDM1AKCNH2KDM1BMAOBRCOR1 | |
| SCHEMBL18596474 | 0.74 | KDM1A (0.44) | KDM1AKCNH2KDM1BMAOBRCOR1 | |
| SCHEMBL17032981 | 0.73 | KDM1A (0.44) | PRKCIDYRK1ADYRK1BKDM1AMAOB | |
| SCHEMBL5584643 | 0.72 | QDPR (0.45) | CLK1DYRK1ADYRK1BCTNNB1WNT3A | |
| SCHEMBL5584639 | 0.72 | NOTUM (0.40) | PRKCICLK1DYRK1ADYRK1BCTNNB1 | |
| SCHEMBL266080 | 0.72 | PRKCI (0.49) | PRKCICLK1DYRK1ADYRK1BCTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108779096-B | Fluorine-substituted cyclopropylamine compounds, and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-07-01 | — | — | CN | disclosed |
| US-10836743-B2 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-17 | — | — | US | disclosed |
| US-20190100507-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-04 | — | — | US | disclosed |
| EP-3431471-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USERS THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100507-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | SETDB1, KDM1B, SETD7 | PRKCI 3067/4885CLK1 2530/4885DYRK1A 1900/4885 |
| US-10836743-B2 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof | SETDB1, KDM1B, SETD7 | PRKCI 3067/4885CLK1 2530/4885DYRK1A 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.